Philip Morris International (PM) Earnings Date & Reports

Key Takeaways

• Analysts anticipate Q1 2026 adjusted diluted EPS (earnings per share) of $1.83, reflecting about 8% year-over-year growth from $1.69 in Q1 2025.
• Consensus revenue estimate stands at $9.85 billion, implying roughly 6% growth compared to $9.3 billion in the prior-year quarter.
• PMI guides Q1 adjusted EPS at $1.80-$1.85, aligning closely with Wall Street views.
• Full-year 2026 adjusted EPS outlook remains $8.38-$8.53, signaling 11%-13% growth.
• Smoke-free products generated 41.5% of 2025 net revenues, up from prior years, with shipment growth of 12.8%.
• Investors watch heated tobacco units (HTU) and oral nicotine pouch volumes for sustained expansion.

Earnings Context and Why It Matters

Philip Morris International's Q1 2026 earnings, due April 22, offer a critical snapshot of its transition to smoke-free products amid regulatory pressures and shifting consumer preferences. Following a stellar 2025 with net revenues topping $40.6 billion and adjusted EPS of $7.54, the company reaffirmed ambitious 2026 guidance. Smoke-free offerings now comprise over 40% of revenues, driving volume and margin growth. For investors, this report gauges execution on high-single-digit to low-teens smoke-free shipment growth targets, organic revenue expansion of 5%-7%, and resilience in combustible cigarette volumes, which are projected to decline about 3%. Broader tobacco industry dynamics, including U.S. nicotine pouch competition and international regulations, heighten the stakes.

Earnings Expectations

Wall Street consensus points to adjusted diluted EPS of $1.83 on $9.85 billion in net revenues for Q1 2026, per 10 analysts tracked by Yahoo Finance. This implies 8.1% EPS growth and 6% revenue expansion from Q1 2025's $1.69 EPS and $9.3 billion. PMI's own Q1 guidance of $1.80-$1.85 adjusted EPS incorporates a favorable 14-cent currency tailwind.

Key metrics in focus include smoke-free shipment volumes, expected to continue double-digit growth after 12.8% in 2025; heated tobacco unit adjusted in-market sales (IMS); and oral smoke-free products like nicotine pouches, which surged 18.5% last year. Investors also eye organic net revenue growth (5%-7% full-year target) and operating margins amid combustibles' ~3% shipment decline. Historically, PM has beaten EPS estimates in recent quarters, with Q4 2025 adjusted EPS of $1.70 meeting consensus on $10.36 billion revenues. Stock reactions have been muted but positive on smoke-free beats.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your stock analysis workflow.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment around PM leans cautiously optimistic, buoyed by reaffirmed full-year guidance and smoke-free traction. The stock has historically gained about 3.5% in the two weeks pre-earnings on average. Risks include U.S. regulatory scrutiny on oral nicotine products and currency volatility, though PMI's international footprint (106 markets) provides diversification. Options implied moves suggest ~4-5% post-earnings volatility, typical for the name.

Forward Outlook and Key Factors to Monitor

Post-Q1, attention will shift to PMI's full-year execution against $8.38-$8.53 adjusted EPS guidance, implying 11%-13% growth. Smoke-free shipment volumes remain pivotal, with targets for high-single-digit to low-teens annual increases across heated tobacco, oral, and e-vapor categories.

Investors should track updates on heated tobacco unit IMS growth (10.5% in 2025) and nicotine pouch momentum, especially amid U.S. competition. Organic operating income growth of 7%-9% hinges on margin expansion in smoke-free gross profit, which rose 18.7% last year organically.

Upcoming catalysts include Q2 results in July, potential regulatory developments, and progress toward 2026-2028 targets: 6%-8% organic revenue growth, 8%-10% operating income growth, and 9%-11% adjusted EPS growth. Cost trends, currency impacts, and cigarette volume declines (~3%) will also shape views on cash flow (~$13.5 billion expected) and capital allocation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations